Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.
Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.
复制标题
DOI：
10.3390/cancers13235994
复制
发表时间：
2021-11-29
期刊：
影响因子：
5.2
通讯作者：
Bjelic-Radisic V
中科院分区：
文献类型：
--
作者：
Elfgen C;Bjelic-Radisic V
在激素受体阳性、HER2 阴性转移性乳腺癌的治疗中，靶向治疗显示出总体生存率的改善，并且近年来已成为一种既定的治疗方法。一些研究结果与其他研究结果相冲突。由于最近发表了多篇关于该主题的新研究文章，本综述旨在具体化当前的相关结果。乳腺癌（MBC）的转移状态影响着全世界数十万女性。在激素受体阳性 (HR+)/人表皮生长因子受体 2 阴性 (HER2−) MBC 中，细胞周期蛋白依赖性激酶 (CDK)4/6 抑制剂可以改善选定患者的无进展生存期 (PFS) 以及总生存期 (OS)，并已被确定为一线和二线疗法。然而，由于 MBC 仍然无法治愈，因此出现了对 CDK4/6 抑制剂的耐药性，需要替代治疗方法。靶向治疗的数据不断成熟，发表数量不断上升。本综述提供了有关临床相关性、患者选择、正在进行的 CDK4/6 抑制剂试验以及进一步的靶向治疗方案的总结和更新。它侧重于临床方面和实用性，以及不良事件和患者报告的结果。
In the treatment of hormone-receptor positive, HER2 negative metastatic breast cancer, targeted therapy showed improved overall survival and it has become an established treatment within recent years. Some study results conflict with others. As multiple new research articles on this topic have been recently published, this review aims to crystallize the current relevant results. A metastatic state of breast cancer (MBC) affects hundreds of thousands of women worldwide. In hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) MBC, cyclin-dependent kinase (CDK)4/6 inhibitors can improve the progression-free survival (PFS), as well as the overall survival (OS), in selected patients and have been established as first- and second-line therapies. However, as MBC remains uncurable, resistance to CDK4/6 inhibitors occurs and requires alternative treatment approaches. Data on targeted therapy continue to mature, and the number of publications has been constantly rising. This review provides a summary and update on the clinical relevance, patient selection, ongoing trials of CDK4/6 inhibitors, and further targeted therapy options. It focuses on clinical aspects and practicability, as well as adverse events and patient-reported outcomes.
登录
查看更多内容
DOI：
10.1016/j.annonc.2020.10.596
发表时间：
2021-03
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Dent S;Cortés J;Im YH;Diéras V;Harbeck N;Krop IE;Wilson TR;Cui N;Schimmoller F;Hsu JY;He J;De Laurentiis M;Sousa S;Drullinsky P;Jacot W
通讯作者：
Jacot W
DOI：
10.1016/j.breast.2020.09.008
发表时间：
2020-12
期刊：
Breast (Edinburgh, Scotland)
影响因子：
--
作者：
Fasching PA;Beck JT;Chan A;De Laurentiis M;Esteva FJ;Jerusalem G;Neven P;Pivot X;Bianchi GV;Martin M;Chandiwana D;Lanoue B;Ridolfi A;Wang Y;Rodriguez Lorenc K;Nusch A
通讯作者：
Nusch A
影响因子：
19
作者：
Goel S;DeCristo MJ;McAllister SS;Zhao JJ
通讯作者：
Zhao JJ
影响因子：
9.3
作者：
Del Re, Marzia;Crucitta, Stefania;Cucchiara, Federico
通讯作者：
Cucchiara, Federico
影响因子：
2.8
作者：
Chang DY;Ma WL;Lu YS
通讯作者：
Lu YS